Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT04155840 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Terminated due to low accrual

Conditions

Lymphoid Leukemia
Non-Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: Copanlisib
BIOLOGICAL: Rituximab
DRUG: Bendamustine

Sponsor

University of Washington

Collaborators

[object Object]